United Therapeutics Gets a Hold Rating from H.C. Wainwright


In a report released today, Andrew Fein from H.C. Wainwright maintained a Hold rating on United Therapeutics (NASDAQ: UTHR), with a price target of $95. The company’s shares closed yesterday at $104.31, close to its 52-week low of $101.99.

According to TipRanks.com, Fein is a 4-star analyst with an average return of 5.4% and a 48.8% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Strongbridge Biopharma Plc, and Cyclacel Pharmaceuticals.

United Therapeutics has an analyst consensus of Hold, with a price target consensus of $137.50.

See today’s analyst top recommended stocks >>

United Therapeutics’ market cap is currently $4.51B and has a P/E ratio of 11.17. The company has a book value ratio of 2.1459.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

United Therapeutics Corp. engages in the development and commercialization of innovative products for patients with chronic and life-threatening diseases. It markets and sells commercial therapies to treat pulmonary arterial hypertension, high-risk neuroblastoma.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts